Pfizer assumed with a Neutral at UBS

UBS assumed coverage of Pfizer (PFE) with a Neutral rating and $25 price target The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.